{"filing":{"accession_number":"0001493152-26-033173","cik":"0001517681","ticker":"PPCB","company_name":"Propanc Biopharma, Inc.","form":"8-K","filing_date":"2026-07-14","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1517681/000149315226033173/form8-k.htm"},"events":[{"id":17831,"run_id":15993,"accession_number":"0001493152-26-033173","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"summary":"The filing discloses both a director departure (Annie Van Broekhoven's retirement and resignation from the Board effective July 8, 2026) and a director appointment (Carlo Campiciano appointed to the Board the same day). While both events occurred, the principal disclosed action centers on the appointment of Campiciano, with detailed biographical information provided about his qualifications, experience as CFO and Company Secretary of MedAdvisor Limited, and expertise in finance, taxation, and corporate governance. The appointment is the forward-looking action that fills the vacancy and is material to investors assessing board composition.","company_name":"Propanc Biopharma, Inc.","ticker":"PPCB","filing_date":"2026-07-14","form":"8-K","submitted_at":null,"items":[{"id":16445,"accession_number":"0001493152-26-033173","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses both a director departure (Annie Van Broekhoven's retirement and resignation from the Board effective July 8, 2026) and a director appointment (Carlo Campiciano appointed to the Board the same day). While both events occurred, the principal disclosed action centers on the appointment of Campiciano, with detailed biographical information provided about his qualifications, experience as CFO and Company Secretary of MedAdvisor Limited, and expertise in finance, taxation, and corporate governance. The appointment is the forward-looking action that fills the vacancy and is material to investors assessing board composition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-14T20:02:39.504614+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":16445,"accession_number":"0001493152-26-033173","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses both a director departure (Annie Van Broekhoven's retirement and resignation from the Board effective July 8, 2026) and a director appointment (Carlo Campiciano appointed to the Board the same day). While both events occurred, the principal disclosed action centers on the appointment of Campiciano, with detailed biographical information provided about his qualifications, experience as CFO and Company Secretary of MedAdvisor Limited, and expertise in finance, taxation, and corporate governance. The appointment is the forward-looking action that fills the vacancy and is material to investors assessing board composition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-14T20:02:39.504614+00:00","company_name":"Propanc Biopharma, Inc.","ticker":"PPCB","filing_date":"2026-07-14"}]}